Restless legs syndrome (RLS) affects 30% of dialysis patients, and is associated with a decreased quality of life.

RLS is more common in patients with kidney disease compared to the general population, the pathophysiology is poorly understood, and current evidence for RLS in end stage renal disease (ESRD) patients is lacking.

The DISCO-RLS study aims to determine whether a fixed, low-dose combination therapy may be beneficial to target the multiple pathways implicated in the pathophysiology of RLS in individuals with kidney disease, while avoiding exposure to higher doses of medications that are associated with adverse events.

DISCO-RLS is a four-treatment crossover randomized controlled trial with a single blind double placebo run-in period.

David Collister, Nephrology Research Fellow, is also a key team member on the DISCO-RLS study.

DISCO-RLS Slides - Download PDF
Study Type

Interventional - Drug

Study Design

Single blind double placebo RCT

NO. of Countries


NO. of Sites


NO. of Participants


Study Period

2019 - 2022



SPOR grant, Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease (Can-SOLVE CKD)

Canadian Institutes of Health Research (CIHR)

Back To Top